AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03425877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Assessment
Description: The subjects will be subjected to the viewing of 21 video clips depicting 6 different emotional states belonging to the FilmStim database validated by Schaefer's studio and collaborators (Schaefer, Nils, Sanchez, \& Philippot, 2010). When viewing the clip, subjects will wear the Microsoft ® Band 2 .and after each movie clip of an evaluation of the stimulus value and activation level perceived by the Self-Assessment Manikin (Bradley \& Lang, 1994) questionnaire). The presentation of movie clip is randomized and does not follow a fixed effect. Between the presentation of each clip a fixed interval of 15 seconds has been inserted in order to induce artifacts and overlap of physiological signals among different emotional valence video clips.
Study NCT03425877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Task
Description: The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).
Study NCT01998672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Px-102
Description: Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
Study NCT01998672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drinking solution
Study NCT03425877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task
Description: This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
Study NCT01094184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
Study NCT03580369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Liquid in vial
Study NCT03296384 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and environmental evaluation
Description: For schizophrenic's patients, specific assessment will be perform
Study NCT01352130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Intravenous Ondansetron 8 mgs
Study NCT01352130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: Intravenous Granisetron 1 mgs
Study NCT03580369 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Lyophilized powder for solution in vial
Study NCT03580369 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid in vial
Study NCT04307511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
Study NCT04307511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
Study NCT04307511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin
Study NCT04307511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin
Study NCT01837927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: Once daily for 52 weeks
Study NCT01837927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Respimat®
Description: Once daily for 52 weeks
Study NCT06276036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identification of specific markers
Description: Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
Study NCT01960829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02816437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OpenBiome Fecal Microbiota Transplantation retention enema
Description: Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
Study NCT00802867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
Description: 0.5 mL, Intramuscular
Study NCT03614819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser group
Description: Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
Study NCT03614819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer Sealing Group
Description: Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
Study NCT00309257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE I, ATA II and Statins
Study NCT00309257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril, Valsartan and Fluvastatin
Description: Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate.
Study NCT04218604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized atrial fibrillation ablation
Description: Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
Study NCT04467164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)
Description: Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
Study NCT04467164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)
Description: Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
Study NCT02562950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 500 mg
Description: Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
Study NCT02562950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
Study NCT02562950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 1000 mg
Description: Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
Study NCT01951885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
Study NCT01951885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
Study NCT01951885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
Study NCT01951885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Patients will receive Mycophenolate beginning on day +1. Patients >40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients \< 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol
Study NCT01951885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (low dose)
Description: MTX 5mg/m2 IV on day +1, +3, +6. If patient\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
Study NCT03905564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination
Description: Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
Study NCT03905564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclegis (Registered Trademark)
Description: Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).
Study NCT03123536 — intervention group
Intervention type: DEVICE
Intervention: Point-of-care Ultrasound
Description: Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
Study NCT00415194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2, IV, every 21 days, six 21 day cycles
Study NCT00415194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2, administered IV, every 21 days, six 21 day cycles
Study NCT00415194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m\^2, administered IV, every 21 days, six 21 day cycles
Study NCT00415194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
Study NCT01751035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction through Family Therapy
Description: RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
Study NCT01751035 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
Study NCT04361903 — intervention group
Intervention type: DRUG
Intervention: Ruxolitinib Oral Tablet
Description: Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours
Study NCT01175811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Premix
Description: Participant dependent dose, administered subcutaneously for 24 weeks
Study NCT01175811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Participant dependent dose, administered subcutaneously for 24 weeks
Study NCT01175811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Participant dependent dose, administered subcutaneously for 24 weeks
Study NCT02931006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Study NCT02931006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bovine milk
Study NCT02400242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-241
Description: Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
Study NCT02400242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg qd dosed on days 1-21 of a 28 day cycle
Study NCT02400242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg qd on days 1, 8, 15, 22
Study NCT00775905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg tablet
Study NCT00775905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 10 mg tablet
Study NCT01780987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
Study NCT01780987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Description: Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
Study NCT01780987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dosing for 24 weeks to target INR range between 1.5-2.5
Study NCT03589586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DermACELL AWM
Description: DermACELL AWM is a sterile, ready to use acellular dermal matrix
Study NCT01529398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensorimotor training (SMT)
Description: The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
Study NCT01529398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training (RT)
Description: The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
Study NCT01529398 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group (CG)
Description: Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
Study NCT01155453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT01155453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Study NCT01324635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO
Study NCT01324635 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Undergo SBRT
Study NCT01324635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study NCT01324635 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT01608386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVC clamping
Description: in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
Study NCT01008852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: 200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
Study NCT01008852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: 200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
Study NCT01008852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: 200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
Study NCT01008852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: 200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
Study NCT01008852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
Study NCT01247246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCV-07
Description: clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
Study NCT01247246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00601809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional conservative treatment (TT)
Description: In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
Study NCT00601809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrografin®: G
Description: The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
Study NCT04295356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P17
Description: subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks
Study NCT04295356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P17
Description: subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks
Study NCT00924729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5% ophthalmic solution
Description: Administer moxifloxacin study drug prior to cataract surgery.
Study NCT00924729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besifloxacin 0.6% ophthalmic suspension
Description: Administer besifloxacin study drug prior to cataract surgery.
Study NCT03179410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10 mg/kg intravenously every 2 weeks
Study NCT03823807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028
Description: Oral,100mg or 200mg ,QD, fasted
Study NCT02269384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Noxious Stimulus
Description: Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.